Can-Fite Biopharma Ltd Sponsored (Israel) - ADR Peer Comparison

$2.24

$-1.16 (-34.12%)

As on 17-Sep-2026 16:15EDT

Market cap

$5 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1

Div. Yield

0 %

Edit

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Market cap ($ Mln)	5	2,710	2,228	2,010	1,862
Revenue ($ Mln)	0	450	549	121	1,044
Net Profit ($ Mln)	-9.91	-188.21	17.88	-57.76	488.78
Net Margin (%)	-2,426.67	-41.86	3.26	-47.60	46.83
RoE (%)	-179.65	-28.46	1.43	-9.91	15.95
Price to Earnings	--	--	128.20	--	3.18
Price-To-Book	0.97	4.47	1.77	3.54	0.49

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Operating Revenue	0.41	460.16	549.96	17.20	1,112.25
Cost of Revenue	0.02	191.08	337.24	5.13	29.74
Gross Profit	0.38	269.08	212.72	12.07	1,082.51
Operating Expenses	10.41	492.65	267.45	74.51	581.12
Operating Profit (EBIT)	-10.03	-223.57	-54.73	-62.44	501.39
Other Income	--	--	--	--	--
Profit before Tax	-9.91	-178.46	522.72	-101.81	300.87
Provision for Tax	--	-2.93	63.78	0.33	-18.62
Profit after Tax (Net Income)	-9.91	-175.54	458.12	-102.14	320.88
Minority Interest	--	--	--	--	--
Consolidated Profit	--	--	--	--	--

Liabilities ($ Mln)

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Shareholder's Funds	5.59	715.50	1,237.93	597.44	3,234.49
Minority Interest	--	--	--	--	--
Non-Current Liabilities	1.19	40.72	186.06	84.62	17.78
Current Liabilities	2.73	416.17	315.78	102.63	152.80
Total Liabilities	9.51	1,172.38	1,753.10	784.68	3,405.07

Assets ($ Mln)

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Non-Current Assets	0.07	153.10	185.76	580.33	326.92
Current Assets	9.44	1,019.29	1,567.35	204.35	3,078.15
Total Assets	9.51	1,172.38	1,753.10	784.68	3,405.07
Total Debt*	0.07	224.26	97.89	128.16	6.92
Net Current Assets	6.71	603.12	1,251.57	101.72	2,926.59

Cashflow ($ Mln)

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Cash From Operating Activities	-9.02	-150.79	-64.66	-49.95	-189.23
Cash Flow from Investing Activities	0.00	307.87	-29.41	0.12	219.35
Cash from Financing Activities	9.72	72.35	7.84	147.34	-3.14
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
ROCE (%)	-176.85	-18.15	41.92	-15.42	10.44
ROE (%)	-179.65	-22.56	45.86	-18.95	10.47
ROA (%)	-106.32	-14.89	30.27	-14.05	8.51
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	-2,426.67	-38.15	83.30	-593.92	28.85
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Revenue Growth (%)	-0.39	0.15	-0.13	1.91	3.04
EBIT Growth (%)	--	--	--	--	--
Net Profit Growth (%)	-25.71	31.73	1,114.23	-16.13	333.15
EPS Growth (%)	-3.92	0.37	11.14	-0.02	3.39
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Price / Earnings	-6.53	-11.11	5.08	-13.58	6.71
Price / Book Value	11.56	2.73	1.88	2.32	0.67
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-5.62	-9.39	-25.58	-18.38	-2.33
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Debt to Equity	0.01	0.31	0.08	0.21	0.00
Short term debt to equity ratio	0.01	0.29	0.02	0.10	0.00
Current Ratio	3.46	2.45	4.96	1.99	20.15
Quick Ratio	--	2.27	4.83	1.77	20.00
Interest Coverage	-710.72	-33.26	-19.05	-3.49	136.71

Operating Efficiency Ratios

	Can-Fite Biopharma Ltd Sponsored (Israel) - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Galapagos NV - ADR
Debtors to sales (%)	18.13	23.06	26.88	86.44	4.78
Asset Turnover	0.04	0.39	0.36	0.02	0.29
Receivable days	67.55	77.60	104.79	380.35	16.53
Inventory Days	--	109.55	49.57	791.94	452.54
Payable days	13,430.61	231.78	47.68	931.00	1,242.94
Cash Conversion Cycle	--	-44.63	106.67	241.30	-773.87

Annual
Quarterly